Market Overview

Vetr Crowd Downgrades Celgene

Share:

The Vetr community on Monday downgraded Celgene Corporation (NASDAQ: CELG) from 4.5 stars (Strong Buy) to 4 stars (Buy). Crowd confidence was very bullish, with 100 percent of the Vetr community reporting a Buy position on the stock.

See how crowdsourced ratings could help you time the market

This upgrade came with news that Celgene would be acquiring Juno Therapeutics Inc (NASDAQ: JUNO) for $9 billion in an effort to expand its cancer treatment efforts.

Despite the downgrade, the Vetr crowd remained bullish, setting a target price of $114.80, which sits well above the current share price of $102.94. Analysts were equally as bullish, with most recent estimates sitting in the $120-$160 range.

 

Related Articles (CELG + JUNO)

View Comments and Join the Discussion!

Posted-In: VetrDowngrades Analyst Ratings

Latest Ratings

StockFirmActionPT
WKHSRoth CapitalMaintains15.0
HCKTRoth CapitalMaintains22.0
ARECRoth CapitalInitiates Coverage On7.5
SLABWells FargoMaintains180.0
PENWells FargoMaintains310.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com